Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abatacept for IgG4-Related Disease
2024-512863-30-00Phase 2Authorised
- Sponsor
- IRCCS Ospedale San Raffaele
- Start
- Apr 2024
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial in IgG4-related disease (IgG4-RD) comparing Abatacept with Placebo (2 arms). Planned start Apr 2024; status: authorised.
02
Drugs
abatacept
03
Conditions
IgG4-related disease (IgG4-RD)
Beyond the preview
Go deeper on 2024-512863-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512863-30-00.